Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases

Journal of Molecular Biology

Volumn 292, Issue 3, 1999, Pages 669-684

  Katz, Bradley A ^a   Luong, Christine ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

pH dependence; Specificity; Structure based drug design; Zn2+ affinity; Zn2+ mediated serine protease inhibitors

Indexed keywords

BENZIMIDAZOLE; CARBONYL DERIVATIVE; NITROGEN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPSIN INHIBITOR; WATER; ZINC ION; BENZIMIDAZOLE DERIVATIVE; BIS(5 AMIDINO 2 BENZIMIDAZOLYL)METHANE; BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE; THROMBIN; TRYPSIN; ZINC;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DISSOCIATION CONSTANT; DRUG BINDING; DRUG STRUCTURE; ENZYME INHIBITION; GEOMETRY; HYDRATION; PH; PRIORITY JOURNAL; ANIMAL; CATTLE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; PROTEIN BINDING; PROTEIN ENGINEERING; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZIMIDAZOLES; BINDING SITES; CATTLE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN ENGINEERING; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THROMBIN; TRYPSIN; ZINC;

EID: 0033600606     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.3071     Document Type: Article

References (46)

1. Allen K. N., Bellamacina C. R., Ding X., Jeffery C. J., Mattos C., Petsko G. A., Ringe D. An experimental approach to mapping the binding surfaces of crystalline proteins. J. Phys. Chem. 100:1996;2605-2611.
2. Ash E. L., Sudmeier J. L., De Fabo E. C., Bachovchin W. W. A low-barrier hydrogen bond in the catalytic triad of serine proteases? Theory versus experiment. Science. 278:1997;1128-1132.
3. Bachovchin W. W., Roberts J. D. Nitrogen-15 nuclear magnetic spectroscopy. The state of histidine in the catalytic triad of α-lytic protease. Implications for the charge-relay mechanism of peptide-bond cleavage in serine proteases. J. Am. Chem. Soc. 100:1978;8041-8047.
4. Bass S. H., Cunningham B. C., Fuh H., Lowman H. B., Matthews D. J., Wells J. A. Metal ion mediated receptor binding of polypeptide hormones. 1992;U.S. Patent WO 92/03478.
5. Bernstein F. C., Koetzle T. F., Williams G. J. B., Meyer E. F. Jr, Brice M. D., Rodgers J. R., Kennard O., Shimanouchi T., Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 112:1977;535-542.
6. Boniface J. J., Allbritton N. L., Reay P. A., Kantor R. M., Stryer L., Davis M. M. pH affects both the mechanism and the specificity of peptide binding to a class II major histocompatibility complex molecule. Biochemistry. 32:1993;11761-11768.
7. Brandstetter H., Kühne A., Bode W., Hubert R., von der Saal W., Wirthensohn K., Engh R. A. X-ray structure of active site-inhibited clotting factor Xa: implications for drug design and substrate recognition. J. Biol. Chem. 271:1996;29988-29992.
8. Brünger A. T. Crystallographic refinement. X-PLOR, Version 3.1: A System for X-ray Crystallography and NMR. 1992a;Yale University Press, New Haven. p. 187-206.
9. Brünger A. T. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992b;472-474.
10. Christianson D. W. Structural biology of zinc. Advan. Protein Chem. 42:1991;281-355.
11. Clark J. M., Jenkins T. E., Katz B. A., Stroud R. M. Metal complexed serine protease inhibitors. 1997;U.S. Patent 5693515.
12. D'Souza U. M., Strange P. G. pH dependence of ligand binding to D2 dopamine receptors. Biochemistry. 34:1995;13635-13641.
13. Ealick S. E., Babu Y. S., Bugg C. E., Erion M. D., Guida W. C., Montgomery J. A., Secrist J. A. III. Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. Proc. Natl Acad. Sci. USA. 88:1991;11540-115443.
14. Finer-Moore J. S., Kossiakoff A. A., Hurley J. H., Earnest T., Stroud R. M. Solvent structure in crystals of trypsin determined by X-ray and neutron diffraction. Proteins: Struct. Funct. Genet. 12:1992;203-222.
15. 2complex. Inorganic Chem. 24:1985;2715-2717.
16. Guo J., Giedroc D. P. Zinc site redesign in T4 gene 32 protein: structure and stability of cobalt(II) complexes formed by wild-type and metal ligand substitution mutants. Biochemistry. 36:1997;730-742.
17. 2+mediates strong and specific interaction of single-chain urokinase with fibrin. J. Biol. Chem. 268:1993;8574-8579.
18. Katz B. A. Binding of biotin to streptavidin stabilizes intersubunit salt bridges between Asp61 and His87 at low pH. J. Mol. Biol. 274:1997;776-800.
19. aof the peptide histidine is less than 3.0. J. Biol. Chem. 272:1997;13220-13228.
20. i~nanomolar inhibitors of serine proteases by binding or epitaxial chemistry on an enzyme surface. Biochemistry. 34:1995;8264-8280.
21. Katz B. A., Clark J. M., Finer-Moore J. S., Jenkins T. E., Johnson C. R., Ross M. J., Luong C., Moore W. R., Stroud R. M. Design of potent selective zinc-mediated serine protease inhibitors. Nature. 391:1998a;608-612.
22. Katz B. A., Liu B., Barnes M., Springman E. B. Crystal structure of recombinant human tissue kallikrein at 2.0 Å resolution. Protein Sci. 7:1998a;875-885.
23. Kelley J. L., McLean E. W., Crouch R. C., Averett D. R., Tuttle J. V. [[(Guaninylalkyl)phosphinico]methyl]phosphonic acids. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 38:1995;1005-1014.
24. 3) as a model for carbonic anhydrase. J. Am. Chem. Soc. 112:1990;5805-5811.
25. Krieger M., Kay L. M., Stroud R. M. The structure and specific binding of trypsin: a comparison of inhibited derivatives and a model for substrate binding. J. Mol. Biol. 83:1974;209-230.
26. Lipscomb W. N., Sträter N. Recent advances in zinc enzymology. Chem. Rev. 96:1996;2375-2433.
27. Lowry T. H., Richardson K. S. Woods J. A. Mechanism and Theory in Organic Chemistry: Reactions of carbonyl compounds. 1976;Harper & Row, Publishers, New York, Hagerstown, San Francisco, London.
28. Magill C., Katz B. A., Mackman R. L. Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system. Emerging Therapeutic Targets. 1999;Ashley PublicationsLtd, London. p. 109-133.
29. Mangel W. F., Singer P. T., Cyr D. M., Umland T. C., Toledo D. L., Stroud R. M., Pflugrath J. W., Sweet R. M. Structure of an acyl-enzyme intermediate during catalysis: (guanidinobenzoyl)trypsin. Biochemistry. 29:1990;8351-8357.
30. Matthews D. J., Wells J. A. Engineering an interfacial zinc site to increase hormone-receptor affinity. Chem. Biol. 1:1994;25-30.
31. Mesecar A. D., Nowak T. Metal-ion-mediated allosteric triggering of yeast pyruvate kinase 2. A multidimensional thermodynamic linked-function analysis. Biochemistry. 36:1997;6803-6813.
32. Presnell S. R., Patil G. S., Mura C., Jude K. M., Conley J. M., Bertrand J. A., Kam C.-M., Powers J. C., Williams L. D. Oxyanion-mediated inhibition of serine proteases. Biochemistry. 37:1998;17068-10881.
33. Raghavan M., Bonagura V. R., Morrison S. L., Bjorkman P. J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry. 34:1995;14649-14657.
34. Renatus M., Bode W., Huber R., Stürzebecher J., Stubbs M. T. Structural and functional analyses of benzamidine-based inhibitors of factor Xa, tPA, and urokinase. J. Med. Chem. 41:1998;5445-5456.
35. Rich K. C., Arnold W. J., Palella T., Fox I. H. Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside posphorylase deficiency. Am. J. Med. 67:1979;172-176.
36. Skrzpczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J. Mol. Biol. 221:1991;1379-1393.
37. Smith J. W. The structural basis of integrin-ligand (RGD) interactions. VI. Cheresh D. A., Mecham R. P. The Role of Divalent Cations in Ligand Binding in Integrins: Molecular and Biological Responses to the Extracellular Matrix. 1994;11-18 Academic Press, San Diego.
38. Somers W., Ultsch M., De Vos A. M., Kossiakoff A. A. The X-ray structure of a growth hormone-prolactin receptor complex. Nature. 372:1994;478-481.
39. Tidwell R. R., Geratz J. D. Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteinases. J. Med. Chem. 21:1978;613-623.
40. Tidwell R. R., Geratz J. D., Dubovi E. J. Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. J. Med. Chem. 26:1983;294-298.
41. Tong L., Qian C., Massariol M.-J., Bonneau P. R., Cordingley M. G., Lagacé L. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature. 383:1996;272-275.
42. Vijayalkakshmi J., Padmanabhan K. P., Mann K. G., Tulinsky A. The isomorphous structures of prethrombin2, hirugen- and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci. 3:1994;2254-2271.
43. Weiner S. J., Kollman P. A., Case D., Singh U. C., Ghio C., Alagona G., Profeta S. Jr, Weiner P. A new force field for molecular mechanical simulation of nucleic acids and proteis. J. Am. Chem. Soc. 106:1984;765-784.
44. Willett W. S., Brinen L. S., Fletterick R. J., Craik C. S. Delocalizing trypsin specificity with metal activation. Biochemistry. 35:1996;5992-5998.
45. York D. M., Darden T. A., Pedersen L. G., Anderson M. V. Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates. Environ. Health Perspect. 101:1993;246-250.
46. Zollner H. Editor of Handbook of Enzyme Inhibitors. 1993;VCH, Weinheim. p. 1012-1014.